Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
2.570
+0.020 (0.78%)
At close: Nov 8, 2024, 4:00 PM
2.599
+0.029 (1.13%)
After-hours: Nov 8, 2024, 7:42 PM EST
Company Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs.
The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC.
It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005.
Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Mersana Therapeutics, Inc.
Country | United States |
Founded | 2001 |
IPO Date | Jun 28, 2017 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 123 |
CEO | Martin Huber |
Contact Details
Address: 840 Memorial Drive Cambridge, Massachusetts 02139 United States | |
Phone | 617 498 0020 |
Website | mersana.com |
Stock Details
Ticker Symbol | MRSN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001442836 |
CUSIP Number | 59045L106 |
ISIN Number | US59045L1061 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Martin H. Huber M.D. | President, Chief Executive Officer and Director |
Brian C. DeSchuytner | Senior Vice President, Chief Financial Officer and Chief Operating Officer |
Dr. Timothy B. Lowinger Ph.D. | Senior Vice President and Chief Science and Technology Officer |
Alejandra Veronica Carvajal J.D. | Senior Vice President, Secretary and Chief Legal Officer |
Mohan Bala Ph.D. | Senior Vice President and Chief Development Officer |
Mikhail Papisov Ph.D. | Co-Founder |
Ashish Mandelia | Chief Accounting Officer |
Jason Fredette | Senior Vice President of Investor Relations and Corporate Communications |
Chuck Miller | Senior Vice President of Regulatory Affairs |
Marc Damelin | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery and Develop. |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 29, 2024 | 144 | Filing |
Oct 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Oct 7, 2024 | 144 | Filing |
Oct 7, 2024 | 144 | Filing |
Oct 7, 2024 | 144 | Filing |
Oct 7, 2024 | 144 | Filing |
Sep 13, 2024 | 144 | Filing |
Aug 13, 2024 | 10-Q | Quarterly Report |
Aug 13, 2024 | 8-K | Current Report |
Jun 11, 2024 | 8-K | Current Report |